	QUICK SEARCH

	Advanced Search

AstraZeneca - Pharma Prospects to 2010

Product Type: Market Research Report

Publication Date: Jun 30, 2008

Download a sample from "The Infoshop", another service of Global Information.

SUMMARY

Following the merger of Astra and Zeneca, AstraZeneca has worked to transform itself into one of the world's leading research-based pharmaceutical companies. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

AstraZeneca, formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, has corporate headquarters in London, and research and development headquarters in Sweden. Since the merger, AstraZeneca has maintained its position as one of the world's leading pharmaceutical companies having never left the top five companies in terms of pharmaceutical sales. It focuses on a number of therapeutic areas: gastrointestinal, respiratory, cardiovascular, pain control/anaesthesia, central nervous system, oncology and infection. AstraZeneca spends almost US$3.4 billion annually on R&D, has sales in over 100 countries and employs over 65,00 people worldwide.

Current Growth Drivers

AstraZeneca now has ten products with global sales of US$1 billion, with five acting as the “engines” for growth in the medium-term:

Nexium (esomeprazole), a proton pump inhibitor used to treat a wide range of acid-related disorders, was the company's top selling product in 2005.
Crestor (rosuvastatin), a statin indicated to treat dyslipidaemia, which has posted strong year-on-year growth since its launch in 2003 in spite of safety concerns raised in the US.
In 2005, Seroquel (quetiapine), an atypical anti-psychotic used to treat schizophrenia and bipolar disorder, become the most prescribed drug in its class in the US.
Arimdex (anastrozole), a treatment for breast cancer in post-menopausal women, posted the highest growth of AstraZeneca's products in 2005, establishing itslef as the world's leading aromatase inhibitor by value.
Symbicort (budesonide+formoterol), an inhaled therapy for asthma and chronic obstructive pulmonary disease (COPD), whose sales in 2005 exceeded the US$1 billion mark despite not having entered the US market yet. An NDA was submitted to the FDA in September 2005, and in July 2006 it received approval for asthma.

Principal Operating Results
Latest Results

EXECUTIVE SUMMARY

Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Key Early-Stage Products
Financial Performance 2005
- Sales and Market Position
- Income
  - Sales, Costs and Operating Income
- Expenditure
  - Capital Expenditure
  - R&D Expenditure
- Divisional Performance
- Geographic Performance
  - During 2005:
  - Sales By Destination
  - Sales By Origin
  - Operating Income By Geographic Segment
  - Total Assets By Geogrpahic Area
Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
  - Employees By Geographic Area (Average)
Product / R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
  - Discontinued Products
- R&D Strategy
  - Discovery
  - Development
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D projects
- Sales Forecast
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas and Sales
R&D Pipeline
Gastrointestinal - Products
- Sales
- Major Launched Products
- Nexium
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Patents
  - Generic Competition/Lawsuits
  - Sales Forecast
  - Clinical Trial Results - NSAID GI Side Effects
  - Clinical Trial Results - ZES and Idiopathic Gastric
  - Hypersecretion
  - Clincial Trial Results - Asthma
  - Clinical Trial Results - Non-GORD Dyspepsia
  - Clinical Trial Results - Coronary Artery Disease
- Others
Gastrointestinal - R&D
- AZD3355
- AZD9056
- AZD9272
Gastrointestinal - Summary
- Growth Potential
- Limiting Factors
Cardiovascular - Products
- Sales
- Major Launched Products
- Atacand
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Patents
  - Sales Forecast
  - Clinical Trial Results - Diabetic Retinopathy
- Crestor
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
  - Competitor Products
  - Generic Competition
  - Sales Forecast
  - Clincial Trial Results - Comparative Studies
  - Clinical Trial Results - Regression Of Atherosclerosis
  - Clinical Trial Results - Renal Outcomes
- Seloken/Toprol
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Patents
  - Generic Competition/Lawsuits
  - Sales Forecast
- Others
Cardiovascular - R&D
- AGI-1067
- AZD0837
- AZD2479
- AZD6140
  - Clinical Trial Results - Acute Coronary Syndrome
- AZD6610
- AZD7009
  - Clinical Trial Results - AF
- AZD8677
- AZD9684
Cardiovascular - Summary
- Growth Potential
- Limiting Factors
Neuroscience - Products
- Sales
- Major Launched Products
- Seroquel
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
  - Competitor Products
  - Patents
  - Generic Competition
  - Lawsuits
  - Sales Forecast
  - Clinical Trial Results - Major Depressive Episodes In BPD
  - Clinical Trial Results - Depression
  - Clinical Trial Results - Aggressive Behaviour In Schizophreniarelated
  - Psychotic Episodes
- Others
Neuroscience - R&D
- AZD1080
- AZD2327
- AZD3480
- AZD5904
- AZD9272
- NXY-059
  - Clinical Trial Results - Acute Ischaemic Stroke
  - Clinical Trial Results - Acute Intracerebral Haemorrhage
- TC-1734
Neuroscience - Summary
- Growth Potential
- Limiting Factors
Cancer- Products
- Sales
- Major Launched Products
- Arimidex
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Patents/Licensees
  - Sales Forecast
  - Clinical Trial Results - ATAC
  - Clinical Trial Results - Combination with Herceptin
- Casodex
  - Sales
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Patents/Licensees
  - Generic Competition
  - Sales Forecast
  - Clinical Trial Results - Prostate Cancer
- Faslodex
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Clinical Trial Results - Breast Cancer
- Iressa
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Clinical Trial Results - ISEL
  - Clincial Trial Results - Breast Cancer
- Zoladex
  - Sales
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Patents
  - Lawsuits
  - Sales Forecast
- Others
Cancer - R&D
- AZD0530
- AZD1152
- AZD1689
- AZD2171
- AZD2281
- AZD4769
- AZD5896
- AZD6244
- CAT-5001
- Zactima
  - Clinical Trial Results - NSCLC
  - Clinical Trial Results - Thyroid Cancer
- ZD4054
Cancer - Summary
- Growth Potential
- Limiting Factors
Respiratory and Inflammation - Products
- Sales
- Major Launched Products
- Pulmicort
  - Sales
  - Key Markets/Indications/Formulations
  - Safety Issues
  - Competitor Products
  - Patents
  - Lawsuits
  - Sales Forecast
- Symbicort
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Patents
  - Sales Forecast
- Others
Respiratory and Inflammation - R&D
- AZD1981
- AZD3342
- AZD5672
- AZD5904
- AZD8309
- AZD8955
- AZD9056
Respiratory and Inflammation - Summary
- Growth Potential
- Limiting Factors
Infection - Products
- Sales
- Major Launched Products
- Merrem
  - Sales
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Others
Infection - R&D
- CytoFab
  - Clinical Trial Results - Severe Sepsis
Infection - Summary
- Growth Potential
- Limiting Factors

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005

APPENDIX 2 - KEY AGREEMENTS

Abbott
- 5th July 2006
Abgenix Inc
- 29th October 2003
Abraxis BioScience Inc
- 27th April 2006
- 28th June 2006
Array BioPharma Inc
- 18th December 2003
- June 2004
- 24th January 2006
- 10th April 2006
- 8th June 2006
- 14th September 2006
Astex Therapeutics Ltd
- 3rd May 2001
- 25th March 2002
- 3rd March 2003
- 7th July 2003
- 19th April 2004
- 27th July 2005
AtheroGenics
- On 22nd December 2005
- 30th January 2006
Avanir Pharmaceuticals
- 11th July 2005
- 3rd January 2006
Biovail Pharmaceuticals
- 2nd May 2005
Cambridge Antibody Technology (CAT)
- 22nd November 2004
Caprion Pharmaceuticals
- 1st November 2005
Dainippon Sumitomo Pharma
- 31st May 2000
- 1st October 2000
- 15th January 2004
Dyax Corp
- 14th May 2002
Dynavax Technologies
- 6th September 2006
Eisai
- 30th July 2004
Eli Lilly
- 20th December 2001
Enzon Pharmaceuticals
- 27th July 2006
Epigenomics AG
- 16th May 2006
Inyx Inc
- 29th June 2004
NPS Pharmaceuticals Inc
- 28th March 2001
- 8th February 2006
Pozen
- 2nd August 2006
- 21st September 2006
Procter & Gamble
- 15th December 1997
- 15th September 2003
- 18th November 2004
Prometheus Laboratories Inc
- 1st December 2004
- 11th January 2005
Protherics
- 8th December 2005
- 12th January 2006
sanofi-aventis
- 17th June 2002
Schering AG
- 27th July 2005
Scil Proteins
- 19th July 2006
SkyePharma PLC
- 7th January 2002
- 28th June 2005
Targacept
- 28th December 2005
- 6th February 2006
The Medicines Company (TMC)
- 6th March 2002
- 19th May 2003
- 18th December 2003
ViroLogic Inc
- 7th March 2005

APPENDIX 3 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL

SUBSIDIARIES / JOINT VENTURES
Subsidiaries
Joint Ventures

APPENDIX 5 - PRODUCT INDEX

Index of Tables

Principal Operating Results
Sales, Costs and Operating Income
Sales By Destination
Sales By Origin
Operating Income By Geographic Segment
Total Assets By Geogrpahic Area
Employees By Geographic Area (Average)
Recent Product Launches
Recent Product Approvals
Key R&D Projects
Major Products, Therapeutic Areas and Sales
R&D Pipeline
Major Launched Products
Major Launched Products
Major Launched Products
Major Launched Products
Major Launched Products
Major Launched Products

Index of Charts

R&D Expenditure and Capital Expenditure
Sales By Destination, 2005
Sales By Origin
Operating Income By Geographic Segment, 2005
Total Assets By Geographic Area, 2005
Employess By Geographic Area, 2005
Forecast Sales of Major Products (2000A-2010E)
Sales of Top Ten Products, 2005
Nexium Sales (2000A-2010E)
Crestor Sales (2000A-2010E)
Seloken Sales (2000A-2010E)
Seroquel Sales (2000A-2010E)
Arimidex Sales (2000A-2010E)
Casodex Sales (2000A-2010E)
Zoladex Sales (2000A-2010E)
Pulmicort Sales (2000A-2010E)
Symbicort Sales (2000A-2010E)
Merrem Sales (2000A-2010E)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity

AstraZeneca - Pharma Prospects to 2010

Publisher: Espicom Business Intelligence

Format	Price	Order
Web Access (Single User License)	US $1130.00
PDF by E-mail (Single User Format)	US $1130.00
Hard Copy	US $1130.00
All orders are processed by "www.the-infoshop.com". www.the-infoshop.com is another Global Information web site. This transfer is entirely safe.

AstraZeneca - Pharma Prospects to 2010

SUMMARY

Current Growth Drivers

TABLE OF CONTENTS

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY AGREEMENTS

APPENDIX 3 - INFRASTRUCTURE

APPENDIX 4 - KEY PHARMACEUTICAL

APPENDIX 5 - PRODUCT INDEX

Index of Tables

Index of Charts